Hospital de Infecciosas Francisco Javier Muniz Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2020
NCT04468009
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Hospital de Infecciosas Francisco Javier Muniz

Active Ingredients

Drugs in Phase 2 Trials (2)

COVID-19 convalescent plasma (1 trial)

oxygen (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronavirus Infections (Phase 2)

Hypoxia (Phase 2)

Severe Acute Respiratory Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2